Navigation Links
Cobalt Technologies Successfully Scales Commercial n-Butanol Production
Date:4/16/2013

MOUNTAIN VIEW, Calif., April 16, 2013 /PRNewswire/ -- Cobalt Technologies ("Cobalt"), a leading developer of next generation bio-based chemicals, today announced the successful completion of a production campaign of n-butanol at a fermentation scale greater than 100,000 liters.  The performance demonstrates scalability by replicating the performance previously obtained at both the 10 liter bench scale and the 4,000 liter pilot scale.  This scale validation is a crucial stepping stone to finalizing any commercial project, since scale up to a commercial fermentor is under 10x, well within industry norms.

With the results achieved during the latest production run, Cobalt demonstrated a clear economic advantage over petroleum-based butanol under current market conditions.  Ongoing process improvements at commercial scale are expected to yield at least a 40 percent cost advantage.

"This most recent production run demonstrates commercial-scale metrics for Cobalt's biobutanol fermentation technology," said Bob Mayer , CEO, Cobalt Technologies. "Cobalt is on track to develop a commercial facility in Brazil and the one-tenth demonstration scale reinforces our confidence in the value and scalability of our technology platform."

The production run was carried out at a US-based contract manufacturing (CMO) facility with minimal modification to their existing aerobic system, highlighting the flexibility of Cobalt's anaerobic technology and showing the robustness of Cobalt's biocatalyst.  The demonstration also provides important validation of Cobalt's ability to take advantage of opportunities to retrofit or co-locate with existing ethanol plants, whether based on sugarcane or corn, for the production of butanol.  The demo supports attractive economics for these deployment models with further value enhancement by replacing food-based sugars with surrounding biomass.

About Cobalt Technologies
Cobalt Technologies is a leader in commercializing the production of bio n-butanol as a renewable chemical and fuel.  N-butanol is a widely used industrial chemical found in paints, lacquers and other surface coatings, with a global market of over $5 billion.  By producing low-cost bio n-butanol, Cobalt's unique technology enables the use of bio n-butanol as a platform molecule for the production of a broad array of fuels and chemicals, including jet fuel, bio-based plastics and synthetic rubber.  Cobalt's technology platform offers a continuous process to efficiently convert diverse non-food feedstocks into biobutanol.  Engineered to achieve low costs through its proprietary biocatalyst, advanced bioreactor, energy efficient design and the use of low-cost feedstock, Cobalt is making biobutanol and its derivatives a cost-effective substitute to petroleum-based chemical products.

Cobalt is based in Mountain View, Calif. Cobalt is backed by leading investors in the cleantech sector, including Pinnacle Ventures, Malaysian Life Sciences Capital Fund, VantagePoint Capital Partners, Parsons & Whittemore, Life Sciences Partners (LSP), @Ventures, Harris & Harris, Burrill and Company and strategic investors including Bunge Global Innovation, LLC.  For more information, please visit http://www.cobalttech.com.


'/>"/>
SOURCE Cobalt Technologies
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cobalt Technologies Hits Key Commercial Milestone with Pretreatment Process Demonstration
2. Isothermal Nucleic Acid Amplification Technologies Market 2012-2017: Molecular Diagnostics, Infectious Disease Testing, Blood Screening, Cancer Research, Rapid Testing
3. Patheon to Feature its Complex Formulation Technologies Expertise at the Upcoming CPhI – P-MEC –ICSE – BioPh – Pharmatec – Medtec Japan – Conference
4. Life Technologies Acquires KDR Biotech Co., LTD., Leading Reagents Distributor
5. Molecular Recognition Elements in Sensing Applications - Biodetection Technologies 2013
6. Life Technologies Launches New Bioinformatics Software Platform Enabling Bio-Design and Gene Synthesis from Next Generation Sequencing Data
7. Core and More Technologies Announces the Most Comprehensive and Cost-effective Paid Search Advertising Packages Available in the Industry Today
8. Life Technologies Chairman And CEO Gregory T. Lucier Named Penn State Outstanding Engineering Alumnus
9. Visit Cole-Parmer at INTERPHEX 2013 and See Versatile Masterflex Technologies
10. Life Technologies Offers New Rapid DNA Platform
11. Consumer Survey Indicates Mouth Guards Worsen TMJ Symptoms As Often As Significantly Improving Them – Holistic Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017  Applied BioMath ( www.appliedbiomath.com ... to drug research and development, today announced ... Inc. for quantitative systems pharmacology (QSP) support ... the treatment of cancer. ... GLP toxicology studies and first-in-human dose predictions ...
(Date:3/29/2017)... ... March 29, 2017 , ... ACEA Biosciences, ... disperses a quarterly travel award to noteworthy scientists who will be presenting research ... its new round of awards are being given to two postdoctoral fellows studying ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... around 7.8% over the next decade to reach approximately $825.4 million ... estimates and forecasts for all the given segments on global as ...
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ -  GeneNews Limited ... BreastSentry™ , a new risk stratification test for breast ... lab, Innovative Diagnostics Laboratory ("IDL"). BreastSentry incorporates a blood-based biomarker ... and lifetime risk for developing breast cancer.   ... BreastSentry measures the ...
Breaking Biology Technology:
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):